HMRI houses world-leaders in severe asthma and other obstructive airway diseases. This productive and comprehensive research programme crosses the translation continuum, from bench to bedside. The research aims to advance understanding of the burden of disease, identify biomarkers and improve assessment tools, and develop and implement innovative treatment approaches.
I am involved in several projects that focus on understanding the disease burden of severe asthma and identifying effective and efficient management strategies in a precision medicine framework. Precision medicine involves the personalisation of healthcare to an individual’s unique profile of symptoms and conditions. Specifically, in my research I examine the Australasian severe asthma registry and clinical trials data to evaluate:
(1) Reduced workplace productivity of people with severe asthma.
(2) Patterns of airway characteristics, comorbidity and risk factors that predict adverse health outcomes or, when treated, most profoundly improve quality of life in people with airway disease.
(3) How medications, such as macrolide antibiotics, influence outcomes in severe asthma.
Ultimately, this research contributes to improving outcomes for people with severe asthma and other obstructive airway diseases via effective personalised, evidence-based management that alleviates asthma symptoms and enhances overall quality of life.